Tern raises £400k through Placing, plans to invest in portfolio companies

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, announces that it has raised £400,000, before expenses, through a placing of 20,000,000 new ordinary shares of 0.02p each in the Company at a price of 2.0 pence per new Ordinary Share, conditional upon admission to trading on AIM.

The Placing Shares will represent approximately 4.9 per cent. of the Company’s enlarged issued share capital following the Placing.  The Issue Price represents a discount of approximately 30.4 per cent. to the mid-market closing price on AIM of 2.875 pence per Ordinary Share on 23 January 2024, being the latest practicable business day prior to the publication of this announcement.

The net proceeds of the Placing will be used to provide the Company with funds to invest further in one or more of Tern’s portfolio companies in the near term and for general corporate purposes.  Further announcements will be made by the Company in due course as appropriate.

CMC Markets UK Plc trading as CMC CapX, acted as the Company’s sole placing agent in respect of the Placing. 

Admission and Total Voting Rights

The Placing has been conducted utilising the Directors’ existing authorities to issue new Ordinary Shares.  The Placing Shares will rank pari passu in all respects with the existing Ordinary Shares.  The Placing is conditional, inter alia, on there being no breach of the obligations under the Placing Agreement entered into between CMC Markets and the Company prior to Admission, and admission of the Placing Shares to trading on AIM becoming effective.  Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM.  It is expected that Admission will become effective and that dealings in the Placing Shares on AIM will commence on or around 30 January 2024.

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, Tern confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 409,676,311 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 409,676,311 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search